Siguler Guff Advisers’s Royalty Pharma RPRX Stock Holding History

Siguler Guff Advisers’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,369,170	Closed	-$60.4M	–	4
2024 Q4	$60.4M	Sell	2,369,170 -1,022,584	-30%	-$27.1M	30.11%	2
2024 Q3	$96M	Hold	3,391,754	–	–	35.68%	2
2024 Q2	$89.4M	Hold	3,391,754	–	–	38.31%	2
2024 Q1	$103M	Hold	3,391,754	–	–	41.04%	1
2023 Q4	$95.3M	Hold	3,391,754	–	–	38.07%	2
2023 Q3	$92.1M	Hold	3,391,754	–	–	47.04%	1
2023 Q2	$104M	Hold	3,391,754	–	–	46.16%	1
2023 Q1	$122M	Hold	3,391,754	–	–	47.65%	1
2022 Q4	$134M	Sell	3,391,754 -3,370,216	-50%	-$141M	64.43%	1
2022 Q3	$272M	Hold	6,761,970	–	–	77.48%	1
2022 Q2	$284M	Hold	6,761,970	–	–	69.86%	1
2022 Q1	$263M	Hold	6,761,970	–	–	59.92%	1
2021 Q4	$269M	Hold	6,761,970	–	–	56.37%	1
2021 Q3	$244M	Hold	6,761,970	–	–	79.54%	1
2021 Q2	$277M	Hold	6,761,970	–	–	82.55%	1
2021 Q1	$295M	Hold	6,761,970	–	–	88.74%	1
2020 Q4	$338M	Buy	+6,761,970	New	+$287M	92.73%	1

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Siguler Guff Advisers's RPRX Position: Q1 2025 in Review

Siguler Guff Advisers sold out of Royalty Pharma (RPRX) in Q1 2025, closing a stake of 2,369,170 shares — an estimated $60.4M sold.

Siguler Guff Advisers first reported a position in RPRX in Q4 2020 and held it in 17 quarters. The position peaked at $338M in Q4 2020. 447 funds tracked by Wall St. Rank hold RPRX as of Q1 2025.

Siguler Guff Advisers reported no remaining Royalty Pharma position as of Q1 2025 after selling out during the quarter.
Siguler Guff Advisers sold 2,369,170 Royalty Pharma shares in Q1 2025, an estimated $60.4M.
Siguler Guff Advisers first reported a position in Royalty Pharma in Q4 2020 and held it in 17 quarters.
Siguler Guff Advisers's Royalty Pharma position peaked at $338M in Q4 2020.
447 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2025.

Based on Siguler Guff Advisers's 13F filing for Q1 2025, filed 29 Apr 2025.